Zejing Pharmaceuticals JAK Inhibitor starts Phase 3 clinical trial for severe alopecia areata

On June 2, the China Drug Clinical Trial Registration and Information Disclosure Platform showed that Zejing Pharmaceuticals launched a Phase 3 clinical trial of Jacketinib Hydrochloride Tablets for the treatment of severe alopecia areata
.

This means that this JAK inhibitor has officially entered the later stage of development

Alopecia areata is the second highest incidence of hair loss in the world.

There are approximately 147 million patients with alopecia areata in the world, and there are about 4 million patients in China

At present, the existing treatment drugs and steroids do not provide meaningful improvement for many patients with alopecia areata, and they urgently need an effective treatment plan
.

JAK inhibitors are considered to be the first to achieve a breakthrough in the treatment of alopecia areata, and they have become one of the popular drug candidates for the treatment of alopecia areata

Just in April this year, Eli Lilly and Company and Incyte's JAK inhibitor baritinib achieved positive results in the second phase 3 clinical trial for the treatment of patients with severe alopecia areata.

It is planned to be in the second half of this year.
Submit a supplementary new drug application (sNDA) to the US FDA

Public information shows that Jacketinib hydrochloride tablets are new small-molecule JAK kinase inhibitor drugs independently developed by Zejing Pharmaceuticals with independent intellectual property rights, and belong to a class 1 new drug
.

Jacketinib hydrochloride can inhibit the non-receptor tyrosine Janus related kinases JAK1, JAK2 and JAK3

This time, Zejing Pharmaceutical initiated a multi-center, randomized, double-blind, placebo-controlled phase 3 clinical trial.

The main purpose is to confirm the effectiveness of Jacketinib hydrochloride tablets in the treatment of severe alopecia areata.
The secondary purpose is to observe hydrochloric acid.

In addition to targeting alopecia areata, Zejing Pharmaceutical is also carrying out a number of clinical studies on Jacketinib hydrochloride tablets.

The indications include: myelofibrosis, idiopathic pulmonary fibrosis, ankylosing spondylitis, moderate to severe plaque psoriasis, Moderate to severe atopic dermatitis and so on

Note: The original text has been deleted

Reference materials:

[1] China Drug Clinical Trial Registration and Information Disclosure Platform.

from http://

[2] The results of the Phase II clinical study of Zektinib tablets in the treatment of intermediate and high-risk myelofibrosis by Zejing Pharmaceuticals were selected in EHA 2021.

Retrieved Apr 25, 2021, from http:// 25/214.
html